Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer
Authors
Keywords
SBRT, SABR, Cyberknife, Boost, Dose escalation, Locally advanced, Stage IIIA, Stage IIIB, Nodal, Age
Journal
Radiation Oncology
Volume 8, Issue 1, Pages 179
Publisher
Springer Nature
Online
2013-07-10
DOI
10.1186/1748-717x-8-179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Positron Emission Tomography for Assessing Local Failure After Stereotactic Body Radiotherapy for Non-Small-Cell Lung Cancer
- (2012) Xu Zhang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Individualized Dose Prescription for Hypofractionation in Advanced Non-Small-Cell Lung Cancer Radiotherapy: An in silico Trial
- (2012) Aswin L. Hoffmann et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control
- (2012) Vikram Rao Bollineni et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Stereotactic Body Radiation Therapy Can Be Used Safely to Boost Residual Disease in Locally Advanced Non-Small Cell Lung Cancer: A Prospective Study
- (2012) Jonathan Feddock et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma
- (2012) Mitchell Machtay et al. Journal of Thoracic Oncology
- PET scans in radiotherapy planning of lung cancer
- (2011) Dirk De Ruysscher et al. LUNG CANCER
- High-Dose Conformal Radiotherapy for Patients With Stage III Non–Small-Cell Lung Carcinoma
- (2010) Hidetsugu Nakayama et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117
- (2010) Jeffrey D. Bradley et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Surgery Versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: Who's Down for the Count?
- (2010) Robert D. Timmerman JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic body radiation therapy: The report of AAPM Task Group 101
- (2010) Stanley H. Benedict et al. MEDICAL PHYSICS
- Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma
- (2008) Nam P. Nguyen et al. CANCER TREATMENT REVIEWS
- Once-Weekly, High-Dose Stereotactic Body Radiotherapy for Lung Cancer: 6-Year Analysis of 60 Early-Stage, 42 Locally Advanced, and 7 Metastatic Lung Cancers
- (2008) Omar M. Salazar et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Non–Small-Cell Lung Cancer
- (2008) Noah B. Arvidson et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation
- (2008) Marta Moreno-Jiménez et al. RADIOTHERAPY AND ONCOLOGY
- Additional PET/CT in week 5–6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
- (2008) Charles Gillham et al. RADIOTHERAPY AND ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More